Logo of Avita Medical (ASX:AVH)Latest Avita Medical (ASX:AVH) News

Page 1
Page 1 of 4

Market Wrap - Week 45 (2 Nov -> 6 Nov) 2026

NEXTDC, Vintage Energy and Embelton recorded the week’s biggest moves, but each came with a different reason and level of risk.
Across resources, takeovers and healthcare, investors rewarded firm deals while selling companies that still need cash or approvals.
Logan Eniac
7 Nov 2026

Healthcare Wrap - Week 45 (2 Nov -> 6 Nov) 2026

Healthcare shares delivered a mixed week as investors rewarded reimbursement and regulatory progress but punished cash calls and dilution. Noxopharm, Pacific Edge and Mayne Pharma led the largest moves, while several companies still face long waits before sales can grow.
Logan Eniac
7 Nov 2026

AVITA Medical raises guidance as RECELL growth pushes cash use towards breakeven

AVITA Medical has raised its 2026 revenue guidance for a second time after third-quarter revenue climbed 53% year on year. The company also drew a further US$10 million under its credit facility and removed its going-concern qualification, although it remains loss-making and highly leveraged.
Victor Sage
6 Nov 2026

Healthcare Wrap - Week 34 (17 Aug -> 21 Aug) 2026

Healthcare shares delivered a mixed week, with strong gains at AVITA Medical, Australian Clinical Labs and CSL despite very different company results.
Investors also weighed new US approvals, clinical trial progress, funding needs and rising sales across the sector.
Logan Eniac
22 Aug 2026

AVITA Medical's PermeaDerm Cuts Wound Care Costs by 70% with Comparable Outcomes

AVITA Medical's PermeaDerm biosynthetic wound matrix delivers clinical outcomes on par with allograft while slashing treatment costs by 70%, according to a new multicenter study.
Ada Torres
19 Aug 2026

Healthcare Wrap - Week 32 (3 Aug -> 7 Aug) 2026

Wellnex led the healthcare market after agreeing to sell Pain Away for up to A$21.3 million. Neuren and Lumos also rose strongly as sales, royalties and product orders improved.
Logan Eniac
8 Aug 2026

AVITA Medical Raises 2026 Revenue Guidance and Targets Q4 Cash Flow Breakeven

AVITA Medical posted robust Q2 2026 results with 18% revenue growth, driven by RECELL and supported by Cohealyx and PermeaDerm, and now expects to reach cash flow breakeven by year-end.
Ada Torres
7 Aug 2026

Market Wrap - Week 20 (11 May -> 15 May) 2026

Capital raisings, resource updates and Medicare news drove the week’s biggest share moves. The sharpest gains came from silver and tungsten juniors, while the heaviest fall came from a deeply discounted equity raising.
Logan Eniac
16 May 2026

AVITA Medical Narrows Q1 Loss as BARDA Deal and Cohealyx Data Boost Growth Prospects

AVITA Medical reported a 4% revenue increase in Q1 2026 with a narrowed net loss, underpinned by a new BARDA contract and promising Cohealyx clinical data. Leadership changes and regulatory approvals support a confident outlook.
Ada Torres
15 May 2026

Market Wrap - Week 16 (13 Apr -> 17 Apr) 2026

Speculative growth names and biotech drove the biggest gains this week, while one consumer staple copped the heaviest selling after cutting guidance. Deal flow stayed busy, but investors were even more responsive to hard numbers: profit upgrades, feasibility studies, contract wins and fresh drilling results.
Logan Eniac
18 Apr 2026

Healthcare Wrap - Week 16 (13 Apr -> 17 Apr) 2026

Big gains came from contracts, approvals and takeover interest, while several capital raisings and debt deals drew a cooler response. Diagnostics, radiopharma and medtech led the week, with buyers rewarding companies that showed clear sales, supply or hospital access.
Logan Eniac
18 Apr 2026

AVITA Medical Cuts Skin Grafting Time by Nearly 20 Days in Interim Cohealyx Study

AVITA Medical’s Cohealyx-I study interim results show a significant acceleration in skin grafting time for full-thickness wounds, reducing mean time to graft from 33.2 to 13.6 days. The ongoing trial’s promising data could reshape wound care protocols.
Ada Torres
15 Apr 2026